Show simple item record

Authordc.contributor.authorWolff Reyes, Marcelo 
Authordc.contributor.authorGiganti, Mark J. 
Authordc.contributor.authorCortés Moncada, Claudia 
Authordc.contributor.authorCahn, Pedro 
Authordc.contributor.authorGrinsztejn, Beatriz 
Authordc.contributor.authorPape, Jean W. 
Authordc.contributor.authorPadgett, Denis 
Authordc.contributor.authorSierra Madero, Juan 
Authordc.contributor.authorGotuzzo, Eduardo 
Authordc.contributor.authorDuda, Stephany N. 
Authordc.contributor.authorMcGowan, Catherine C. 
Authordc.contributor.authorShepherd, Bryan E. 
Admission datedc.date.accessioned2018-05-14T17:24:51Z
Available datedc.date.available2018-05-14T17:24:51Z
Publication datedc.date.issued2017
Cita de ítemdc.identifier.citationPlos One 12(6): e0179769es_ES
Identifierdc.identifier.other10.1371/journal.pone.0179769
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/147721
Abstractdc.description.abstractBackground In Latin America, the first wave of HIV-infected patients initiated highly active antiretroviral therapy (HAART) 10 or more years ago. Characterizing their treatment experience and corresponding outcomes across a decade of HAART may yield insights relevant to the ongoing care of such patients and those initiating HAART more recently in similar clinical settings. Methods This retrospective study included adults initiating HAART before 2004 at 8 sites in Argentina, Brazil, Chile, Haiti, Honduras, and Mexico. Patient status (in care, dead, or lost to follow-up [LTFU]) was assessed at 6-month intervals for 10 years, along with CD4 count and HIV-1 viral load (VL) for patients in care. Results 4,975 patients (66% male) started HAART prior to 2004; 45% were not antiretroviral-naive. At 1, 5, and 10 years, rates of mortality were 4.2%, 9.0%, and 13.6% respectively. LTFU rates for the same periods were 2.4%, 10.9%, and 24.2%. Among patients remaining in care at 10 years, 84.4% were estimated to have VL <= 400 copies/mL (Haiti excluded) and median baseline CD4 increased from 158 to 525 cells/mm(3). Only 11.4% of all patients remained on their first regimen, 12.6% were on their second, 11.5% were on their third, and 23.0% were on their fourth or subsequent regimen. Outcomes were generally better for patients who were not antiretroviral-naive, except for viral suppression. Heterogeneity among sites was substantial. Conclusions Despite advanced disease and predominant use of older antiretrovirals, a large percentage of early HAART initiators in this Latin American cohort were alive and in care with sustained virologic suppression and progressive immune recovery after 10 years.es_ES
Patrocinadordc.description.sponsorshipNational Institute of Allergy and Infectious Diseases (NIAID) / National Cancer Institute (NCI) / Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) as part of the International epidemiologic Databases to Evaluate AIDS (IeDEA), U01 Al069923es_ES
Lenguagedc.language.isoenes_ES
Publisherdc.publisherPublic Library Sciencees_ES
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile*
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/*
Títulodc.titleA decade of HAART in Latin America: Long term outcomes among the first wave of HIV patients to receive combination therapyes_ES
Document typedc.typeArtículo de revista
Catalogueruchile.catalogadortjnes_ES
Indexationuchile.indexArtículo de publicación ISIes_ES


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Chile
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile